We’re proud to announce the Department of Defense-funded PROMPT (Partial REBOA Outcomes Multicenter ProspecTive) Study, the first prospective in-human study of Partial REBOA. Read more here:
prweb.com/releases/prytime_m…
#REBOA #pREBOA #data #clinicaltrial #research #medicine #trauma
teammates who put others first, staying calm under pressure, and carrying a standard of excellence that comes from somewhere deeper than a job description.
The uniforms might have changed, but the discipline, the pride, and the sense of mission certainly have not.
(3/4)
1
1
33
The 74th Detroit Trauma Symposium is almost here.
Find our booth for a hands-on demo of the pREBOA-PRO™ — the only FDA-cleared catheter for partial occlusion.
1
37
Our Trauma Multicenter Case Presentation brought clinicians together again this week — sharing real REBOA cases, real decisions, and honest lessons from the field.
At Prytime Medical, we take clinical education seriously, and we believe meaningful support starts with listening.
1
28
These calls are built on exactly that. The patients, teams, and challenges are different at every hospital, and the fastest way to learn is hearing how peers adapted to theirs.
1
15
This isn't a one-size-fits-all framework — just clinicians building knowledge and confidence, case by case.
Thank you to every physician who shared their experiences today.
12
And preserved physiology buys options. The study's authors describe a "window of opportunity to pre-interventionally optimise the physiology of the patient" — time for CT, CT angiography, and a safe pivot to less invasive hemorrhage control.
1
9
We are grateful to have spent the weekend in Galveston, TX at PAS² with the clinicians and researchers advancing accreta care. The work and advancements you are doing for those affected by placenta accreta spectrum is critical.
(1/2)
1
1
50
This week, we are proud to attend the 8th Annual Meeting of the Pan-American Society for Placenta Accreta Spectrum (PAS²), hosted by UT Medical Branch.
(1/2)
1
2
43






